CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
ConditionClassical Hodgkin Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age6-29
SponsorNew York Medical College
About this trial
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
Eligibility criteria
Qualifiers
Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo re-induction therapy.
Confirmatory re-biopsy of relapsed CD30+ cHL prior to study entry.
12 months from end of therapy OR 3-12 months from end of therapy with ≤3 cycles of treatment and no radiation NO B symptoms NO extra nodal disease at relapse NO relapse in a prior radiation field Stage at Diagnosis = IB, IIB, IIIA
Disqualifiers
None
Trial design
Treatments tested in this trial
- CD30+ CAR T-cells
- Bendamustin
- Fludarabine
Treatment groups
12 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
New York Medical College
Lead sponsor
University of North Carolina
Collaborator
Memorial Sloan Kettering Cancer Center
Collaborator
Source ClinicalTrials.gov